Moderna has launched a rare public attack on the US Food and Drug Administration, warning that an “unpredictable” regulator could weaken America’s lead in drug innovation. During the call, company leaders specifically argued that the FDA’s unpredictable decision-making undermines industry momentum. The comments came during the company’s Friday analyst call. This was just days after the FDA declined to accept…
Tag: Earnings
-
Adcock Ingram: A picture of resilience in a challenging market
Pharmaceutical stalwart Adcock Ingram presents a compelling case for investors seeking resilience amidst potential market turbulence. The group boasts a robust track record, with a mere 3% dip in headline earnings per share (HEPS) during the challenging Covid-impacted year of 2021. It was their worst annual performance in a decade. Since 2015, Adcock has delivered an impressive 16.2% compound annual…